The NanoGrow™ tube is printed with the words “Patented Cetosomes Technology”. This page explains what that technology is, where it is described, and the limits of the published evidence. [1]
What a Cetosome® is
US Patent 9,084,818 B2 describes topical dermal delivery compositions built from self-assembling nanoparticles with cetylated components. The granted claims specify a nanoparticle zeta potential of −20 to −100 mV (or +20 to +100 mV); the patent reports measured particle diameters of 60–850 nm. [2] It builds on earlier work on cetylated fatty-ester penetrant complexes, US Patent 8,394,759 B2. [3]
| Property | As described in the patent |
|---|---|
| Structure | Self-assembling nanoparticles with cetylated components |
| Surface charge (claimed) | −20 to −100 mV, or +20 to +100 mV |
| Measured diameter | 60–850 nm |
| Intended use | Topical dermal delivery compositions |
| Assignee | Cymbiotics, Inc. |
Why a delivery system matters
The outer layer of skin is an efficient barrier. Molecules above roughly 500 daltons pass through it poorly, which is why the vehicle an ingredient is carried in can matter as much as the ingredient itself. [4] Lipid vesicles have been studied for three decades as a way to carry ingredients into the upper layers of the skin, and their particle size and uniformity influence how they behave. [5] [6]
The connection to NanoGrow™
NanoGrow™ is manufactured by Cymbiotics Biopharma Pvt. Ltd., Baddi, and marketed by Monocure Pharma, Indore. The Cetosome® patents above are assigned to Cymbiotics, Inc. [1] [2]
Monoskin has not published characterisation data for the vesicles in NanoGrow™ — for example their size, charge, or which of the declared ingredients they carry. For formulation documentation, email Monoskin.
What the clinical studies tested
Two published Indian studies evaluated cetosomal minoxidil. A retrospective, real-world study across 66 centres (n = 261) assessed cetosomal minoxidil 5% alone or with finasteride 0.1%; its authors were employees of the product’s marketing company. [7] A randomised, open-label study across five centres (80 enrolled, 40 analysed) compared 5% cetosomal minoxidil with a 5% alcohol-based minoxidil solution in Indian men. [8]
NanoGrow™ contains no minoxidil. These studies describe minoxidil products that used a cetosomal vehicle; their results cannot be transferred to NanoGrow™.
What we can and cannot say
- Can: NanoGrow™ is made with a delivery technology described in granted US patents for topical dermal delivery.
- Can: the vehicle is designed to carry ingredients in nanoparticles rather than as a simple solution.
- Cannot: claim that the vehicle changes hair growth, shedding or density with NanoGrow™ — no study of the NanoGrow™ formula has been published.
References
- Monoskin. NanoGrow™ Non-Minoxidil Hair Serum. Pack and official product information.
- Barathur RR, Bookout JB (Cymbiotics, Inc.). Topical dermal delivery compositions using self assembling nanoparticles with cetylated components. US 9,084,818 B2. 2015.
- Barathur RR, Bookout JB (Cymbiotics, Inc.). Transdermal delivery of medicaments with combinations of cetylated fatty ester penetrant complexes. US 8,394,759 B2. 2013.
- Bos JD, Meinardi MMHM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Experimental Dermatology. 2000.
- Elsayed MMA et al. Lipid vesicles for skin delivery of drugs: reviewing three decades of research. International Journal of Pharmaceutics. 2007.
- Danaei M et al. Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems. Pharmaceutics. 2018.
- Kerure A et al. Real-World Effectiveness, Safety, and Tolerability of Cetosomal Minoxidil 5% Alone and a Fixed Drug Combination of Cetosomal Minoxidil 5% With Finasteride 0.1% in the Management of Androgenetic Alopecia (Inbilt Study). Cureus. 2023.
- Sattur S et al. Comparative Clinical Study Evaluating the Efficacy and Safety of Topical 5% Cetosomal Minoxidil and Topical 5% Alcohol-Based Minoxidil Solutions for the Treatment of Androgenetic Alopecia in Indian Men. Cureus. 2023.